Literature DB >> 29169287

Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?

Christopher Florkowski1, Andrew Don-Wauchope2, Nuria Gimenez3, Karina Rodriguez-Capote4, Julien Wils5, Annalise Zemlin6.   

Abstract

Point-of-care testing (POCT) is the analysis of patient specimens outside the clinical laboratory, near or at the site of patient care, usually performed by clinical staff without laboratory training, although it also encompasses patient self-monitoring. It is able to provide a rapid result near the patient and which can be acted upon immediately. The key driver is the concept that clinical decision making may be delayed when samples are sent to the clinical laboratory. Balanced against this are considerations of increased costs for purchase and maintenance of equipment, staff training, connectivity to the laboratory information system (LIS), quality control (QC) and external quality assurance (EQA) procedures, all required for accreditation under ISO 22870. The justification for POCT depends upon being able to demonstrate that a more timely result (shorter turnaround times (TATs)) is able to leverage a clinically important advantage in decision making compared with the central laboratory (CL). In the four decades since POCT was adapted for the self-monitoring of blood glucose levels by subjects with diabetes, numerous new POCT methodologies have become available, enabling the clinician to receive results and initiate treatment more rapidly. However, these instruments are often operated by staff not trained in laboratory medicine and hence are prone to errors in the analytical phase (as opposed to laboratory testing where the analytical phase has the least errors). In some environments, particularly remote rural settings, the CL may be at a considerable distance and timely availability of cardiac troponins and other analytes can triage referrals to the main centers, thus avoiding expensive unnecessary patient transportation costs. However, in the Emergency Department, availability of more rapid results with POCT does not always translate into shorter stays due to other barriers to implementation of care. In this review, we apply the principles of evidence-based laboratory medicine (EBLM) looking for high quality systematic reviews and meta-analyses, ideally underpinned by randomized controlled trials (RCTs), looking for evidence of whether POCT confers any advantage in clinical decision making in different scenarios.

Entities:  

Keywords:  Point-of-care testing; evidence-based laboratory medicine; turnaround times

Mesh:

Year:  2017        PMID: 29169287     DOI: 10.1080/10408363.2017.1399336

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  19 in total

1.  Rapid genotyping of bacterial leaf blight resistant genes of rice using loop-mediated isothermal amplification assay.

Authors:  M K Prasannakumar; Buela P Parivallal; Chennappa Manjunatha; Devanna Pramesh; Karthik S Narayan; Gopal Venkatesh; Sahana N Banakar; H B Mahesh; Ramu S Vemanna; K T Rangaswamy
Journal:  Mol Biol Rep       Date:  2021-01-04       Impact factor: 2.316

2.  Admission Emergency Department Point-of-care Biomarkers for Prediction of Early Mortality in Spontaneous Intracerebral Hemorrhage.

Authors:  Eugenia-Maria Muresan; Adela Golea; Stefan Cristian Vesa; Iulia Givan; Lacramioara Perju-Dumbrava
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

3.  Reducing Point-of-care Blood Gas Testing in the Intensive Care Unit through Diagnostic Stewardship: A Value Improvement Project.

Authors:  Michael J Tchou; Sally May; John Holcomb; Ethan Tanner-Edwards; Kathy Good; Matthew Frazier; Erika L Stalets; Maya Dewan
Journal:  Pediatr Qual Saf       Date:  2020-06-24

4.  Diagnosis of acute serious illness: the role of point-of-care technologies.

Authors:  Gregory L Damhorst; Erika A Tyburski; Oliver Brand; Greg S Martin; Wilbur A Lam
Journal:  Curr Opin Biomed Eng       Date:  2019-09-16

Review 5.  Evaluation of Molecularly Imprinted Polymers for Point-of-Care Testing for Cardiovascular Disease.

Authors:  Brian Regan; Fiona Boyle; Richard O'Kennedy; David Collins
Journal:  Sensors (Basel)       Date:  2019-08-09       Impact factor: 3.576

6.  A Multicenter Observational Prospective Cohort Study of Association of the Prehospital National Early Warning Score 2 and Hospital Triage with Early Mortality.

Authors:  Francisco Martín-Rodríguez; Raúl López-Izquierdo; Carlos Del Pozo Vegas; Juan F Delgado-Benito; Carmen Del Pozo Pérez; Virginia Carbajosa Rodríguez; Agustín Mayo Iscar; José Luis Martín-Conty; Carlos Escudero Cuadrillero; Miguel A Castro-Villamor
Journal:  Emerg Med Int       Date:  2019-07-01       Impact factor: 1.112

7.  A deep learning backcasting approach to the electrolyte, metabolite, and acid-base parameters that predict risk in ICU patients.

Authors:  Albion Dervishi
Journal:  PLoS One       Date:  2020-12-17       Impact factor: 3.240

8.  Experience of point-of-care HbA1c testing in the English National Health Service Diabetes Prevention Programme: an observational study.

Authors:  Emma Barron; Shivani Misra; Emma English; W Garry John; Michael Sampson; Max O Bachmann; Julian Barth; Nick Oliver; K G M M Alberti; Chirag Bakhai; Simon O'Neill; Bob Young; Nicholas J Wareham; Kamlesh Khunti; Susan Jebb; Jenifer Smith; Jonathan Valabhji
Journal:  BMJ Open Diabetes Res Care       Date:  2020-12

9.  Matching Development of Point-of-Care Diagnostic Tests to the Local Context: A Case Study of Visceral Leishmaniasis in Kenya and Uganda.

Authors:  Michel Bengtson; Mitasha Bharadwaj; Astrid Ten Bosch; Hellen Nyakundi; Damaris Matoke-Muhia; Cees Dekker; Jan-Carel Diehl
Journal:  Glob Health Sci Pract       Date:  2020-09-30

10.  A tandem giant magnetoresistance assay for one-shot quantification of clinically relevant concentrations of N-terminal pro-B-type natriuretic peptide in human blood.

Authors:  Fanda Meng; Weisong Huo; Jie Lian; Lei Zhang; Xizeng Shi; Aldo Jesorka; Yunhua Gao
Journal:  Anal Bioanal Chem       Date:  2021-02-23       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.